Industry Buzz Growing Rapidly Around MINDCURE’s iSTRYM

  • Public and private psychedelics companies with clinic operations are currently putting a high priority in finding a digital therapeutics platform to (a) increase treatment efficiencies and (b) rapidly scale up commercialization
  • MINDCURE’s iSTRYM platform is the first mover here – and turning heads across the psychedelic drug industry





For serious investors, one part of “investing” is playing detective. Keeping their nose to the ground, looking to sniff-out the latest trends in the sector(s) in which they are focused.

Those serious investors in psychedelic stocks will want to take a closer look at Mind Cure Health (CAN:MCUR / US:MCURF) and its new-and-proprietary iSTRYM digital therapeutics platform.

iSTRYM is trending. More on this shortly.

Digital therapeutics is moving healthcare into the 21st century

For investors who haven’t been following the development of IP technology in the psychedelics industry, digital therapeutics is emerging as an integral component of mental health treatment, and healthcare in general.

Digital therapeutics platforms add enormous efficiency in delivering healthcare services, but companies are also discovering these platforms are invaluable tools for rapidly scaling-up treatment models – in a cost-effective manner.

Next-generation platforms are taking this healthcare tool to the next level: integrating AI into these software platforms. Through AI, digital therapeutics can also greatly enhance the treatment model itself. Monitoring medication and treatment regimens, and even providing real-time assessments of routine data.

Therapists are freed up from many of the administrative functions that previously consumed much of the day. This allows practitioners to treat more patients and/or elevate the standard of care.

Consequently, most of the public companies with a clinics component either have already put in place their own platform, or are in the process of doing so. One of these public companies is Awaken Life Sciences (CAN:AWKN / US:AWKNF).

In what has been a tough year for psychedelic stocks to date, AWKN is up nearly 40% in 2021. The market likes Awaken Life Sciences. And what does Awaken like? iSTRYM.

iSTRYM: first and best in digital therapeutics

At the recent Wonderland psychedelics conference in Miami, Awaken’s CEO, Anthony Tennyson was interviewed along side MINDCURE’s President and CEO, Kelsey Ramsden. A central part of that interview was Tennyson explaining how iSTRYM was going to greatly facilitate the rapid scale-up and commercialization of its clinical treatment model.

The Wonderland conference was hosted by MicroDose, a leading investment platform in showcasing public and private companies and educating investors on the psychedelics industry. As part of Wonderland, Microdose held its first annual psychedelics awards.

Nominated for “B2B tech company of the year” in the psychedelics industry was Mind Cure Health, and its iSTRYM platform.

However, the buzz about iSTRYM extends well beyond the Wonderland investor conference. MAXIM Group just put out new coverage of MINDCURE (with a price target of USD$1 / CAD$1.25). MAXIM sees the potential of iSTRYM to be “a best in class tool for psychedelic medicine.”

In turn, all this industry buzz around iSTRYM is also attracting interest from other business writers covering the psychedelics space. One site has put out a flurry of recent coverage on MINDCURE, and iSTRYM features prominently in framing the MCUR value proposition.

Psychedelic Stock Watch has been ahead of the curve in identifying the potential of digital therapeutics, in general, and the exciting commercial potential of iSTRYM, in particular. Back in April, we published:

Digital Therapeutics: Optimizing Psychedelics Therapies With Next-Generation IP

… More recently, the company has taken iSTYRM to the next level. On April 13, 2020, MINDCURE announced a partnership with Speak AI. The goal: enhancing iSTRYM with AI in order to maximize the benefits of its digital therapeutics platform.

MINDCURE’s CEO, Kelsey Ramsden, connected the dots for investors.

“We will be building custom integrations with Speak Ai for the iSTRYM platform that allow us to marry sentiment with biometric data, location, weather, and a variety of other variables to help optimize our integration protocols and provide individuals with quantified care at scale globally, all with the stated goal of advancing Mental Wealth, rooted in data.”

Investors won’t have to wait for MCUR to start benefitting from the AI-improved iSTRYM platform. Just prior to that news release (on April 8, 2021), MINDCURE announced that iSTRYM would be deployed in Canada’s first psychedelics-based treatment center – ATMA Journey Centers.

More recently, MINDCURE added to the iSTRYM buzz with another news release of its own.

A November 4th update reported that the Company has exceeded its Q4 2021 goal for clinic partners for iSTRYM, with a total of 20 clinic partners now lined up for iSTRYM. It was only on August 26th that MINDCURE announced that the minimum viable product (MVP) version of iSTRYM was ready for release.

Equally important, with 20 clinic partnerships already in place, this puts MINDCURE on target to achieve its next distribution goal for iSTRYM: 150 partner clinics for iSTRYM by the end of 2022.

With CAD$15.6 million in cash and equivalents as of August 31, 2021, MINDCURE is abundantly capitalized to not only fully roll out iSTRYM, but to also execute on other high-priority initiatives: MINDCURE’s ibogaine synthesis, manufacturing and drug development, as well as the Company’s newest R&D initiative, Project Desire.

Psychedelic medicine is the future of mental health care, iSTRYM can be a major driver of growth

Psychedelic medicine remains the best-and-only option to address a Mental Health Crisis that is rapidly spiraling out of control – due to the failure of conventional therapies to provide even adequate treatment options.

This means the potential to scale up psychedelics-assisted therapies is practically infinite, a commercialization dream. iSTRYM is a next-generation, hi-tech tool to turbocharge the growth of psychedelic medicine.

No wonder the buzz around iSTRYM is growing.

For investors interested in learning more about iSTRYM and MINDCURE itself, stay tuned. Psychedelic Stock Watch will be releasing a full-length feature looking back on the development of iSTRYM – and looking ahead to its future commercial potential.





DISCLOSURE: The writer holds shares in Mind Cure Health. Mind Cure Health is a client of Psychedelic Stock Watch.
 
Disclaimer:
Please see our full PRIVACY POLICY

The content on Psychedelic Stock Watch is not personalized investment advice. Our employees strive to give smart, stimulating commentary, but are not licensed to address or give advice on individual investment situations. Nothing you receive from Psychedelic Stock Watch should be considered personal investment advice. Any investments recommended by Psychedelic Stock Watch should only be made after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. All investments carry risk of significant loss.

Please see full disclaimers at https://psychedelicstockwatch.com/disclaimer applicable to all content provided by PSW , wherever published or re-published: https://psychedelicstockwatch.com/statements-policies

Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This release/advertorial does not constitute an offer or solicitation to buy or sell any securities or individualized investment advice. This is a native advertisement, meaning it is an informational paid marketing piece. PsychedelicStockWatch.com (PSW) makes no recommendation that the securities of the issuers profiled or discussed on this website should be purchased, sold or held by viewers, whether or not viewers learn of the profiled issuers through our website or otherwise. Please review all investment decisions with a licensed investment advisor.

PSW receives media support and payments from the issuer or third-party companies that have contracted with the issuer ranging from approximately $25,000 to $150,000 to publish and/or distribute advertisements on behalf of the issuer. The issuer and/or third-party companies that have contracted with the issuer have not promised exclusivity to PSW and may hire additional publishers or advertisers on behalf of the issuer. PSW retains any excess sums after expenses as its compensation. PSW may be paid for services using cash, options, restricted shares, free-trading shares, or shares of other unrelated issuers, and thus PSW and its owners, operators and affiliates may benefit from any increase in the share prices of the profiled issuers.

PSW and/or its owners, operators and affiliates make no representations about their short-term or long-term investment horizons and may be selling shares of stock at the same time the profile (or other information) is being disseminated to potential investors; PSW is under no obligation to, and will not, advise any party when it or its affiliates decide to buy or sell shares. Investors must make all investment decisions based on their own judgment of the market and the particular securities.

This release/advertorial contains forward-looking statements that involve risks and uncertainties. This release/advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured issuer. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s),” “anticipate(s),” “plan(s),” “expect(s),” “project(s),” “will,” “make,” “told,” “could,” “might,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the issuer to differ materially from these indicated by such forward-looking statements. Certain statements contained herein are forward-looking statements as defined in Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the issuer or PSW or contained in this release/advertorial are not guarantees of future performance, and that the issuer’s actual results may differ materially from those set forth in the forward-looking statements. We undertake no obligation to update any statements made herein. Differences in results can be caused by various factors including, but not limited to, the issuer’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this release/advertorial contains “forward-looking statements.” Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. More information on the issuer that is the subject of this release/advertorial may be found at http://www.sec.gov where readers can review all public filings submitted by the issuer. PSW is not a certified financial analyst, investment advisor, broker/dealer, or licensed in the securities industry in any manner. The information in this advertorial is subjective opinion and may not be complete, accurate or current and was paid for by the issuer, creating a potential conflict of interest.
 



 
Industry buzz (cover) by Psychedelic Stock Watch is licensed under N/A
© 2019 - 2021 Psychedelic Stock Watch, Privacy Policy, Disclaimer